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Introduction and background
===========================

Tumor lysis syndrome (TLS) is a major, life-threatening oncological emergency where hasty damage of tumor cells ends in a constellation of critical metabolic derangements. These constitute hyperuricemia, hyperphosphatemia, hyperkalemia, and hypocalcemia, leading to an acute kidney injury (AKI), which further worsens TLS metabolic abnormalities and outcomes \[[@REF1]-[@REF5]\]. TLS divided into spontaneous TLS (STLS) and treatment-related (TTLS). Although TLS is widely known to occur in patients with rapidly proliferating chemosensitive hematologic diseases, it can seldom happen in solid tumors. Recent papers were published indicating prostate cancer (PRCA) as being one of the solid tumors that can exceptionally rarely be complicated by TLS \[[@REF6]-[@REF24]\]. This study\'s objective is to investigate the clinical characteristics, management, and outcomes of TLS, a rare oncologic emergency, in patients with PRCA.

Review
======

Aim of the study

This review aims to examine the available published information on the clinical characteristics, treatment, and outcomes of TLS in patients with prostate cancer.

Patients and methods

Literature Search Strategy

A systematic analysis through a comprehensive literature search was conducted and pooled with cases from our institution. We searched PubMed, Medline, ScienceDirect, and Scopus for \"tumor lysis syndrome\" and \"prostate cancer.\" The identified list of cases and abstracts were reviewed and screened for any additional articles of interest from reference lists.

Data Extraction and Statistical Analysis

We extracted data on age at diagnosis, histological subtypes, prostate-specific antigen, Gleason score, diagnostic radiology, comorbid status, treatment, and outcomes were also recorded when available. Four cases from our institution were included in our analysis. We interpreted the pooled data and summarized it through descriptive statistics using central tendency and dispersion measures.

Results

We recognized 18 publications where TLS occurred in the setting of PRCA (14 case reports and four meeting abstracts). Out of the 18 cases of TLS, we identified 12 TTLS cases and six STLS cases. Furthermore, we identified four cases of STLS diagnosed in our institutional database. The final cohort was consistent with a total of 22 PRCA patients with TLS.

The demographics, clinicopathologic features, and survival outcomes of 22 cases of TLS in PRCA are summarized in Table [1](#TAB1){ref-type="table"}. The mean age (± SD) was 63.5 (±14.5) years. The median prostate-specific antigen (PSA) was 374 (range 66.7-10,867 ng/mL). Most cases were prostate adenocarcinoma (except prostate rhabdomyosarcoma in one case, prostate small cell carcinoma (SCC) in two cases, and pathology type not documented in four cases). High-grade Gleason 8+ PRCA documented in 80% of cases with available data, including two cases of prostate SCC. All cases (100%) reported distant metastases. Of the cases with available data, 100% had bone metastasis and 52% had liver metastasis. Ten cases (45.5%) had STLS. In contrast, 12 TLS cases (54.5%) were associated with a variety of treatment regimens before developing TLS; out of these, six patients received chemotherapy (27.3%), three cases received hormonal treatment (13.6%), two received radiation therapy (9.1%), and one case developed TLS after treatment with methylprednisolone for pembrolizumab-induced acute liver injury (4.5%). All patients had elevated lactate dehydrogenase (LDH) with other biochemical variables such as uric acid, potassium, phosphorus, and creatinine. All patients received aggressive supportive therapy, 11 (50%) underwent hemodialysis, 12 (54.5%) received rasburicase, and three (13.6%) received allopurinol (Figure [1](#FIG1){ref-type="fig"}).

###### Summary of available publications and our hospital data for characteristics of patients with TLS in PRCA

PRCA: prostate cancer; TLS: tumor lysis syndrome; PSA: prostate-specific antigen; Mets: metastases locations; Ref: references; ND: no data; STLS: spontaneous TLS; SCC: small cell carcinoma; LN: lymph nodes; TURBT: transurethral resection of bladder tumor

  --------------------------- ------ ----- --------------------------- --------------- -------- ---------------------------------------- ----------------------------------------------------------------- -------------------- ------------- --------------------------------------------- --------- --------------
  Author                      Year   Age   Histology                   Gleason score   PSA      Mets                                     Treatment preceding TLS                                           Time to TLS (days)   Rasburicase   Other management                              Outcome   Ref
  Sorscher                    2004   80    Adenocarcinoma              3+3             348      Bone                                     Docetaxel, dexamethasone                                          1                    No            Furosemide                                    Died      \[[@REF6]\]
  Tanvetyanon and Choudhury   2004   77    Adenocarcinoma              ND              10,867   Bone, liver                              Flutamide, goserelin                                              6                    No            Supportive therapy                            Died      \[[@REF7]\]
  Wright et al.               2005   60    Adenocarcinoma              3+4             5520     Bone                                     Paclitaxel                                                        1                    No            Hemodialysis                                  Died      \[[@REF8]\]
  Lin et al.                  2007   72    Adenocarcinoma              ND              66.7     Bone, liver                              Flutamide, leuprolide, dexamethasone, medroxyprogesterone         21                   No            Hemodialysis, furosemide, allopurinol         Died      \[[@REF9]\]
  Hashem et al.               2010   73    Adenocarcinoma              ND              ND       Bone                                     STLS                                                              ND                   No            Hemodialysis                                  Died      \[[@REF10]\]
  Zulqarnain et al.           2012   56    Prostate SCC                ND              6.1      Bone, LN, liver, lungs                   Chemotherapy                                                      2                    Yes           Exchange transfusion for methemoglobinemia    Alive     \[[@REF11]\]
  Kaplan et al.               2012   60    Adenocarcinoma              5+4             300      Bone                                     Radiation therapy to shoulder                                     6                    Yes           Sodium bicarbonate                            Died      \[[@REF12]\]
  Nguyen and Ticona           2014   72    Adenocarcinoma              ND              ND       Bone, LN                                 STLS                                                              ND                   Yes           Supportive therapy                            Alive     \[[@REF13]\]
  Watanabe and Tanaka         2014   16    Prostate rhabdomyosarcoma   ND              ND       Bone, LN                                 STLS                                                              ND                   Yes           Supportive therapy                            Alive     \[[@REF14]\]
  Mazzoni                     2016   62    Adenocarcinoma              ND              ND       Bone, LN, bladder                        Radiation, TURBT, leuprolide, bicalutamide                        ND                   Yes           Hemodialysis, sodium bicarbonate              Died      \[[@REF15]\]
  Serling-Boyd et al.         2017   56    Adenocarcinoma              5+4             548      LN, liver                                STLS                                                              ND                   Yes           Sodium bicarbonate, furosemide, allopurinol   Died      \[[@REF16]\]
  Ignaszewski and Kohlitz     2017   69    Adenocarcinoma              ND              ND       Bone, liver                              STLS                                                              ND                   Yes           Hemodialysis, sodium bicarbonate              Died      \[[@REF17]\]
  Bhardwaj and Varma          2017   67    ND                          ND              4500     Bone, LN, liver                          Docetaxel                                                         3                    No            Supportive therapy                            Died      \[[@REF18]\]
  Gongora et al.              2018   46    Adenocarcinoma              4+4             917      Bone, LN, liver, lungs                   Carboplatin, etoposide                                            5                    Yes           Supportive therapy                            Alive     \[[@REF19]\]
  McGhee-Jez et al.           2018   49    Adenocarcinoma              ND              24.9     Bone                                     STLS                                                              ND                   No            Hemodialysis, allopurinol, prednisone         Alive     \[[@REF20]\]
  Oshima et al.               2019   77    ND                          5+4             \>1000   Bone, LN, liver                          Cabazitaxel                                                       3                    Yes           Hemodialysis, sodium bicarbonate              Died      \[[@REF21]\]
  Sharma and Lane             2019   59    ND                          ND              2.1      LN, liver, adrenal glands                Enzalutamide                                                      30                   Yes           Hemodialysis                                  Died      \[[@REF22]\]
  Mayer and Zarouk            2019   71    ND                          ND              ND       ND on metastatic sites                   Methylprednisolone for pembrolizumab-induced acute liver injury   3                    Yes           Hemodialysis                                  Alive     \[[@REF23]\]
  Case 1, Wang                2016   72    Adenocarcinoma              4+5             746      Bone, LN                                 STLS                                                              ND                   No            Supportive therapy                            Alive     \[[@REF24]\]
  Case 2, Wang                2018   53    Adenocarcinoma              4+4             374      Bone, LN, lungs                          STLS                                                              ND                   No            Hemodialysis                                  Alive     \[[@REF24]\]
  Case 3                      2018   82    Adenocarcinoma              ND              ND       Bone, LN, liver                          STLS                                                              ND                   No            Supportive therapy                            Alive     \[[@REF24]\]
  Case 4                      2019   69    Prostate SCC                ND              ND       Bone, LN, liver, lungs, brain, adrenal   STLS                                                              ND                   Yes           Hemodialysis                                  Alive     \[[@REF24]\]
  --------------------------- ------ ----- --------------------------- --------------- -------- ---------------------------------------- ----------------------------------------------------------------- -------------------- ------------- --------------------------------------------- --------- --------------
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The mortality rate was 75% among 12 cases of TTLS, with a median survival of 4.5 days (range 1-30) from diagnosis of TLS to death, and 30% in the 10 cases with STLS. There was no reported mortality in the four cases recognized and managed in our institution.

Discussion

In our cohort, several findings are noteworthy. First, the high mortality in TLS most often occurs in PRCA patients with advanced-stage metastatic disease, significant disease burden, high Gleason score, and aggressive histology. Second, TLS in PRCA, particularly TTLS, displays poorer prognosis when compared to hematologic malignancies \[[@REF25]-[@REF27]\]. Third, we recognized two patients with primary prostate SCC. Similar to SCC in other locations, prostatic SCC histology has been linked to TLS and is known for its aggressive biological behavior and rapid proliferation rate \[[@REF28]-[@REF29]\]. Molecular studies identified a germline breast cancer susceptibility 2 (BRCA2) gene mutation in both cases. BRCA-positive PRCA patients tend to have a higher Gleason score, higher PSA, higher grade of tumor proliferation, and higher rate of metastasis, predisposing them to an early-onset, aggressive, and potentially fatal disease as compared to patients with BRCA negative tumors \[[@REF30]-[@REF33]\]. 

Research in animal models proposed additional mechanisms that might explain the higher mortality of TLS. Studies in mice found disseminated microemboli from lysed tumor cells during the histopathological postmortem examination; these result in widespread tissue damage, multiorgan failure, and death \[[@REF34]-[@REF35]\]. Those findings closely mimic the human autopsy findings of disseminated tumor embolism leading to massive tissue organ necrosis and death \[[@REF36]-[@REF37]\]. Furthermore, concurrent disseminated intravascular coagulation was proposed as a probable mechanism that could synergistically lead to increased mortality in patients with TLS through common pathogenesis and pro-inflammatory cytokine-mediated processes \[[@REF13]-[@REF14]\]. Further, upon investigating this entity, cytokines, especially TNF-alfa (TNFα) and Interferon-gamma (IFNγ), are considered key mediators of what is known as a \"cytokine storm,\" first described by Aikawa in 1996 \[[@REF38]\]. The cytokine storm reported having a positive correlation with the tumor burden and was thought to play a vital role in the pathophysiology of TLS \[[@REF39]-[@REF41]\]. A cohort by Nakamura et al. found an elevated serum interleukin-6 (IL-6), IL-8, and IL-10 cytokine levels in all treatment-related TLS patients and reported a 100% survival rate after receiving continuous hemodiafiltration for cytokine removal \[[@REF41]\].

We were able to identify four cases of TLS in PRCA patients managed in our 450+ bed hospital, two of which were in the last 24 months. Since our last publication on this matter, we continued to have improved outcomes through our continued efforts for early identification of TLS in patients with PRCA \[[@REF24],[@REF27]\].

Limitations of the study

Due to the inherent nature of retrospective studies, we were not able to perform a comprehensive assessment of factors that may impact the prognosis of TLS in prostate cancer patients, including the performance status and comorbid conditions. Larger sample size would further contribute to the stratification of the risk of patients based on treatment type before TLS development. Despite the limitations, this systematic review presents the most updated real-world insight regarding the diagnosis and prognosis of TLS in patients with metastatic prostate cancer. Our study will contribute to the evolving understanding of TLS in solid neoplasms and have implications for future cancer treatment paradigms in the era of targeted therapy.

Conclusions
===========

Our study underscores that TLS is a real oncologic emergency, especially among patients with advanced PRCA. A heightened state of readiness orchestrated with increased attention to improve early detection of electrolytes abnormalities is immensely important for early TLS recognition and prompt intervention in patients with newly diagnosed metastatic PRCA even before starting cancer therapy. Further research is needed to determine the true incidence and molecular markers for TLS in solid tumors, which could, therefore, aid in improving outcomes.
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